Physician profile
Dalvir Gill
NPI 1285017491
$4,303.03
in general payments reported to CMS, 2019-2025
33 companies · $843 in 2025
The $843 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.25 · 2022: $2,122 · 2023: $367 · 2024: $924 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,249.70 | 2022 | |
| Boston Scientific Corporation | $360.27 | 2022 | |
| Merck Sharp & Dohme LLC | $278.03 | 2023-2025 | Verquvo, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $252.72 | 2023-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $247.07 | 2021-2025 | Farxiga, Brilinta, Fasenra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $207.09 | 2023-2025 | Lifevest |
| Shockwave Medical, INC | $175.42 | 2022-2025 | |
| Cardiovascular Systems INC. | $153.13 | 2022 | |
| Novo Nordisk INC | $145.28 | 2024-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.22 | 2022-2025 | Jardiance |
| Amgen INC. | $120.31 | 2022-2025 | Tezspire, Repatha |
| Philips North America LLC | $119.78 | 2022-2025 | Coronary Other |
| Abiomed | $92.51 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $67.31 | 2024 | Arcalyst |
| Biotronik INC. | $65.54 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.17 | 2023-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $57.54 | 2024-2025 | Glassia |
| Novartis Pharmaceuticals Corporation | $53.02 | 2024-2025 | |
| Genzyme Corporation | $48.63 | 2023-2024 | |
| Abbott Laboratories | $47.84 | 2023 | Xience Skypoint, Cardiomems |
| Regeneron Healthcare Solutions, INC. | $45.02 | 2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $44.66 | 2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $41.91 | 2024-2025 | |
| United Therapeutics Corporation | $39.49 | 2025 | Tyvaso |
| Heartflow, INC. | $31.40 | 2024 | |
| Silk Road Medical, INC. | $30.87 | 2022 | |
| Grifols USA, LLC | $29.34 | 2025 | Prolastin-C Liquid |
| Acist Medical Systems, INC. | $27.13 | 2024 | |
| Terumo Medical Corporation | $21.91 | 2022 | |
| Pfizer INC. | $15.53 | 2024 | |
| Baxter Healthcare | $14.55 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $13.86 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $13.78 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalvir Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.